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I. INTRODUCTION 
 
Analytical chemistry is the study of the chemical composition of natural and artificial 
materials that deals with the separation, identification and determination of components in a 
sample. In other words, it is the art and science of determining what matter is and how much 
of  it exists , which requires background knowledge of chemical and physical concepts.  
Analytical chemistry ia a  measurement science consisting of a set of powerful ideas and 
methods that are useful in all fields of science and medicine. Hence ,it plays a vital role in the 
development of science. 
Pharmaceutical analysis plays a major role today, derives its principles from various 
branches of science like chemistry, physics, electronics, nuclear science etc. Analytical 
method used for science of sampling, defining, isolating, concentrating, set error limits 
validate and verify results through calibration and standardization. Analytical method is a 
specific application of a technique to solve an analytical problem.  
Analytical instrumentation plays an important role in the production and evaluation of 
new products and in the protection of consumers and the environment. This instrumentation 
provides the lower detection limits required to assure safe foods, drugs, water and air.  
Analytical chemistry has been split into two main types, 
Qualitative analysis- identifying functional groups or elements, or information regarding the 
presence or absence of one or more components of  the  sample taken. 
Quantitative analysis- amount of analyte present in the sample such as mass or volume is 
determined using appropriate analytical method. 
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Instrumental methods of analysis:  
 The newer methods for separating and determining chemical species are collectively as 
instrumental methods of analysis. Most of the instrumental techniques fit in to  one of the 
three principle areas such as 
 Spectroscopic Techniques 
 Chromatographical Techniques 
 Electrochemical Techniques 
 Hyphenated Techniques 
 Miscellaneous Techniques 
Spectroscopic techniques: 
 Spectroscopy is the branch of science dealing with the study of interaction of 
electromagnetic radiation with matter. The most important consequence of such interaction is 
that energy is absorbed, scattered or emitted by the matter in discrete amounts called quanta. 
Examples: 
 Ultra-violet spectrophotometry  
 nuclear magnetic resonance spectrometry 
 atomic spectrometry 
 infrared spectrometry 
 X-Ray spectrometry 
 Raman spectrometry 
 
Chromatography techniques: 
Chromatography is a technique which separates components in a mixture due to the 
differing time taken for each component to travel through a stationary phase when carried 
through it by a mobile phase. 
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Examples: 
 Gas chromatography 
 High performance liquid chromatography 
 Super critical-fluid chromatography 
Electrochemical techniques: 
Electroanalytical methods measure the potential(volts) or current (amps) in an cell  
electrochemical containing analyte. 
Examples: 
 Potentiometric techniques 
 Coulometry techniques 
 Voltametric techniques 
 Amperomeric techniques 
 Electrogravimetry 
Hyphenated techniques:  
Hyphenated techniques combine chromatographic and spectral methods to exploit the 
advantages of both. 
Examples: 
 GC-MS (Gas Chromatography – Mass Spectrometry) 
 GC-IR (Gas Chromatography – Infrared Spectroscopy) 
 MS-MS (Mass Spectrometry – Mass Spectrometry)  
 ICP-MS (Inductivity Coupled Plasma Mass Spectrometry) 
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Miscellaneous techniques: 
Examples : 
 Thermal analysis 
 Mass spectrometry 
 Kinetic techniques 
 
CHROMATOGRAPHY
(19)
 
 A Russian botanist , Mikhail tswett(1872-1919)  was credited with the first use 
chromatography in 1906 when he separated plant pigments such as chlorophylls and 
xanthophylls. he passed them through a glass column packed with calcium carbonate. These 
pigments are coloured and thus the technique was named using the greek terms „chroma‟ 
meaning „colour‟ and „graphein‟ meaning to write chromatography. 
Chromatography is the collective term for the separation of mixtures. The mixture is 
dissolved in a fluid called the mobile phase which carries it through a structure holding 
another material called the stationary phase. The various constituents of mixture travel at 
different speeds, causing them to separate. The separation is based on differential partitioning 
between the mobile and the stationary phases. Subtle differences in a compound‟s partition 
coefficient result in differential retention on the stationary phase and thus changing the 
separation. 
CLASSIFICATION OF CHROMATOGRPHY: 
Based on the principles Involved: 
 Absorption Chromatography 
 Partition Chromatography 
 Ion-exchange Chromatography  
 Size exclusion Chromatography  
 Affinity Chromatography  
 Electrophoretic Chromatography 
   Chiral chromatography  
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Types of Chromatography: 
Chromatography characterized as a separation method based on the differential migration 
of solute through a system of two phases, one is mobile phase another one is stationary phase.   
Chromatography is a technique by which the components in a sample, carried by the 
liquid or gaseous phase, are resolved by sorption, desorption steps on the stationary phase. 
Table no-1-classification of chromatography 
General 
Classification 
Specific Method 
Name 
Stationary Phase Type of Equilibrium 
Liquid 
Chromatography (LC) 
Mobile Phase = liquid 
Liquid-liquid or 
partition 
Liquid adsorbed on a 
solid 
Partition between immiscible 
liquids 
Liquid-bonded 
phase 
Organic species bonded 
to a solid surface 
Partition between liquid and 
a bonded surface 
Liquid-solid or 
adsorption 
Solid Adsorption 
Ion exchange Ion-exchange resin Ion exchange 
Size exclusion Liquid in interstices of a 
polymeric solid 
Partition/sieving 
Gas Chromatography 
(GC) 
Mobile Phase = gas 
Gas-liquid Liquid adsorbed on a 
solid 
Partition between gas and 
liquid 
Gas-bonded 
phase 
Organic species bonded 
to a solid surface 
Partition between liquid and 
bonded surface 
Gas-solid Solid Adsorption 
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HIGH PERFORMANCE LIQIUD CHROMATOGRAPHY 
The analytical technique of high performance liquid chromatography is used extensively 
throughout the pharmaceutical industry. It is used to provide information on the composition 
of drug related samples. High Performance Liquid Chromatography (HPLC) is one mode of 
chromatography, one of the most used analytical techniques. Chromatographic process can be 
defined as separation technique involving mass-transfer between stationary and mobile phase. 
HPLC  utilises a liquid mobile phase to separate the components of a mixture. The stationary 
phase can be a liquid or  a solid phase. These components are first dissolved in a solvent, and 
then forced to flow through a chromatographic column under a shigh pressure. In the column, 
the mixture separates into its components. The amount of resolution is important, and is 
dependent upon the extent of interaction between the solute components and the stationary 
phase. The stationary phase is defined as the immobile packing material in the column. The 
interaction of the solute with mobile and stationary phases can be manipulated through 
different choices of both solvents and stationary phases. As a result, HPLC acquires a high 
degree of versatility not found in other chromatographic systems and it has the ability to 
easily separate a wide variety of chemical mixtures. 
                 Process of separation of HPLC 
                                                   
 
  
 
  
 
   HPLC separation is based on interactions and differential partition of sample between 
the mobile phase and stationary phase. 
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TYPES OF HPLC: 
Based on Modes of Chromatography: 
 Normal phase chromatography 
 Reverse phase chromatography 
Based on Principle of Separation: 
 Adsorption chromatography 
 Partition chromatography 
 Ion exchange chromatography 
 Size exclusion chromatography 
 Affinity chromatography 
 Chiral  phase chromatography 
Base on Elution Technique: 
 Isocratic separation  
 Gradient separation 
Based on the Scale of Operation: 
 Analytical HPLC  
 Preparative HPLC 
Normal phase chromatography: 
Normal phase chromatography is chromatographic technique that uses organic solvents 
for mobile phase and a polar stationary phase 
Reverse phase chromatograghy: 
Modifying  the polar nature of silanol group by chemically reacting silica with organic 
silanes. The objective was to make less polar or non polar so that polar solvents can be used to 
separate water-soluble polar compounds. Since the ionic nature of the chemically modified 
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silica is now reversed i.e. it is non-polar or the nature of the phase is reversed. The 
chromatographic separation carried out with such silica is referred to as reversed- phase  
chromatography. 
The term reversed-phase describes the chromatography mode that is just the opposite of 
normal phase, namely the use of a polar mobile phase and a non-polar [hydrophobic] 
stationary phase.Today, because it is more reproducible and has broad applicability, reversed-
phase chromatography is used for approximately 75% of all HPLC methods. Most of these 
protocols use as the mobile phase an aqueous blend of water with a miscible, polar organic 
solvent, such as acetonitrile or methanol. This typically ensures the proper interaction of 
analytes with the non-polar, hydrophobic particle surface. A C18–bonded silica [sometimes 
called ODS] is the most popular type of reversed-phase HPLC packing. 
Adsorption chromatography: 
Adsorption chromatography is one of the oldest types of chromatography around. It  
utilizes a mobile liquid or gaseous phase that is adsorbed onto the surface of a stationary solid 
phase. The equilibration between the mobile and stationary phase accounts for the separation 
of different solutes. 
Compounds such as silica acid(silica gel), aluminium oxide, calcium carbonate, 
magnesium carbonate, magnesium oxide and cellulose may be used as stationary phase, the 
choice of any particular adsorbent and solvent elution system is dependent on the separation 
to be achieved. 
Partition chromatography: 
This form of chromatography is based on a thin film formed on the surface of a solid 
support by a liquid stationary phase. Solute equilibrates between the mobile phase and the 
stationary liquid. Mobile phase may be either a liquid or a gas. 
  The stationary solid surface is coated with a 2nd liquid (the Stationary Phase) which is 
immiscible in the solvent (Mobile) phase. Partitioning of the sample between two phases 
delays or retains some components more than others to effect separation.  
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Ion exchange chromatography: 
The stationary bed has an ionically charged surface of opposite charge to the sample ions. 
This technique is used almost exclusively with ionic or ionizable samples. The stationary 
phase is an ion exchange resin, and separations are governed by the strength of the 
interactions between solute ions and the exchange sites on the resin.  The stronger the charge 
on the sample, the stronger it will be attracted to the ionic surface and thus, the longer it will 
take to elute. The mobile phase is an aqueous buffer, where both pH and ionic strength are 
used to control elution time. 
Size exclusion chromatography: 
It is also known as gel permeation or filtration, separation is based on the molecular size 
or hydrodynamic volume of the components. Molecules that are too large for the pores of the 
porous packing material on the column elute first, small molecules that enter the pores elute 
last, and the elution rates of the rest depend on their relative sizes. 
Ion-pair/affinity chromatograghy: 
Separation is based on a chemical interaction specific to the target species. The more 
popular reversed phase mode uses a buffer and an added counter-ion of opposite charge to the 
sample with separation being influenced by pH, ionic strength, temperature, concentration of 
and type of organic co-solvent(s). Affinity chromatography, common for macromolecules, 
employs a ligand (biologically active molecule bonded covalently to the solid matrix)which 
interacts with its homologous antigen (analyte) as a reversible complex that can be eluted by 
changing buffer conditions. 
Chiral chromatography: 
Separation of the enantiomers can be achieved on chiral stationary phases by formation 
of diastereomers via derivatizing agents or mobile phase additives on a chiral stationary 
phases. When used as an impurity test method, the sensitivity is enhanced if the enantiomeric 
impurity elutes before the enantiomeric drug. 
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The S-(+) ketamine form is more potent than the R-(-) form. In addition the R-(-) 
enantiomer may cause post-operative effects. Chromatographic techniques provide fast and 
accurate methods for enantiomeric separation and allow quantitation using appropriate 
detection  devices. These methods are considered to be most useful for chiral separations. 
These two approaches are: 
  Indirect – which utilizes  derivatizing agents 
  Direct- this uses chiral stationary phases or chiral mobile phase additives. 
HPLC INSTRUMENTATION: 
 Schematic diagram of  high performance liquid chromatography 
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INSTRUMENTATION: 
The essential of the high performance liquid chromatography are: 
 Solvent reservoir  
 Mobile phase 
 Pump system 
 Sample Injection System 
 Column 
 Detector 
Solvent reservoir: 
An HPLC system begins with the solvent reservoir made up of glass or stainless steel  
which contains the solvent used to carry the sample through the system. The reservoir is often 
equipped with an online degasser which removes the dissolved gases usually oxygen and 
nitrogen, which interfere by forming bubbles. The solvent should be filtered with an inlet 
solvent filter to remove any particles which damage the system. Degasser may consist of 
vaccum pumping system, distillation system, system devices for heating and solvent stirrer.  
Mobile phase: 
The mobile phase as indicated is the moving phase. Either the mobile or stationary phase 
is polar and the other is Non-polar. A common polar phase is Methanol, and .non-polar is 
hexane. The mobile phase carries the mixture through the column stationary phase. The solute 
can interact with the mobile phase as well as with the stationary phase. Sufficient solubility of 
solute molecules in the mobile phase must be ensured in order to prevent precipitation. 
Pumping system: 
HPLC pumping  system  are  required to deliver metered amounts of mobile phase at a 
constant flow rate. Pumping system that deliver solvent from one or more reservoirs are 
available. Generating   pressure  from 6000 psi to 10000 psi pulse free output. Flow rates from 
0.1 to 10 ml/min. HPLC pump can be classified in to the following groups according to the 
manner in which they operate. 
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Constant displacement pump: 
 Reciprocating piston pump 
 Syringe drive pump 
Constant pressure pump: 
 simple gas displacement pump 
 pneumatic amplifier pump 
Constant displacement pumps: 
Constant displacement pumps maintains a constant flow rate through the column 
irrespective of changing conditions within the column. One form of constant displacement 
pump is a motor-driven syringe type pump where a fixed volume of solvent is forced from the 
pump to the column by a piston driven by a motor. Such pumps as well as  providing uniform 
solvent flow rates, also yields a pulse less solvent flow which is important as certain  detectors 
are sensitive to changes in solvent flow rate. 
Reciprocating pumps:  
Reciprocating pump is most commonly used form of constant displacement pump. The 
piston moved by a motorized crank, and entry of solvent from reservoir to the pump chamber 
and exit of solvent to the column is regulated by check valves. On the compression stroke 
solvent is forced from the pump chamber into the column. During the return stroke the exit 
check valve closes and solvent is drawn in via the entry valve to the pump chamber, ready to 
be pumped onto the column on the next compression stroke. Such pumps produce pulses of 
flow and pulse of flow and pulse dampeners are usually incorporated into the system to 
minimizing this pulsing effect.  
Constant pressure pump: 
Constant pressure pumps produce a pulse less flow through the column, but any decrease 
in the permeability of the column will result in lower flow rates for which the pump, and the 
gas in turn forces the solvent from the pump chamber into column. The use of an intermediate 
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solvent between the gas and the eluting solvent reduces the chances of dissolved gas directly 
entering the eluting solvent and causing problems during the analysis. 
Pneumatic pumps: 
Pneumatic pumps are the simplest where a the mobile phase is pushed out of the mobile 
phase container by the pressure of a pressurized gas. The flow is dependent on the back 
pressure of the column and usually the flow is limited to pressures below2000 psi.  
Sample injection system: 
In liquid chromatography, liquid samples may be injected directly and solid samples need 
only be dissolved in appropriate solvent. In HPLC systems, automatic sampling devices are 
incorporated where the sample is introduced with the help of auto samplers and 
microprocessors. With these devices, sample is first transferred at atmospheric pressure from 
a syringe into a sample loop. Turning the valve from load to inject position connects the 
sample loop are transferred on to the column. A variety of loop volumes is available, 
commonly 10-50 µl.  
Columns: 
The columns used for HPLC are generally made up 316 grade of stainless steel and are 
manufactured so that they can withstand pressures of 5.5 X 10
7
 pa (8000 psi) with 6.35 mm in 
external diameter, 4.6 mm in internal diameter and 25 cm long. The best columns are 
precision bored with an internal mirror finish which allows efficient packing of the column. 
Porous plugs of stainless steel or Teflon are used in the ends of the columns to retain the 
packing material. The plug must be homogenous to ensure uniform flow of solvents through 
the column. Materials other than stainless steel that are used for columns include glass, glass 
lined steel tube or other inert plastics. 
Analytical column- length of the column ranges from 5-30 cm and inner diameter 4 to 5 mm.  
particle size of packing is 5 to 10 µm.   
Preparative column- length of the column 25 cm long and 2-5 diameter with 15-100µm. 
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Guard column-  
The guard column is effective preventing the analytical column from being alternated by 
those impurities. The guard column is a smaller version of the analytical column; packed with 
the same type of gels as that is in analytical column. The guard column is placed before the 
analytical column, thus any potential impurities that may cause damages is trapped inside the 
guard column before it reaches the analytical column. 
 
DETECTORS: 
 HPLC detectors pass a beam of light through a column effluent as the fluid passes  
through a low-volume flow cell. Variation in light are recorded and a chromatograph is 
generated. 
LC detectors are basically of two types 
1. Bulk property detectors: 
 It compares overall changes in a physical property of the mobile phase with and without 
an eluting solute. e.g. refractive index, dielectric constant or density.  
 
2. Solute property detectors:  
 It responds to a physical property of the solute which is not exhibited by the pure mobile 
phase. e.g. UV absorbance, fluorescence or diffusion current. Such detectors are about 1000 
times more sensitive giving a detectable signal for a few nanograms of sample. 
 Some   types of high performance liquid chromatography detectors are used in analysis 
mostly are UV detectors, Fluorescence detectors etc 
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Hplc detectors: 
 UV-Visible absorbance detector (UV-VIS) 
 Fluorescence detector 
 Refractive Index (RI) 
 Electrochemical (ECD) 
 UV-Visible absorbance detector (UV-VIS) 
 Photo-diode array detector (PDA) 
 Conductometric detector 
 Mass detectors (MS) 
 Radiochemical detection 
 Chiral detector (Polarimetric & circular dichrosim) 
UV-Visible absorbance detector (UV-VIS): 
UV detectors function on tha capacity of may compounds to absorb light in the 
wavelength range 1880 to 350 nm. The sensor cell usually consist of cylindrical cavity light 
from a UV light sources passes through the sensor on to a photoelectric cell, the output from 
which  is modified and presented on a potentiometric recorder, a computer screen, or printer. 
By interposing a monochromater  between the light source and the cell, light of a specific 
wavelength can be selected for detection and thus improve the detector selectivity.  
Light scattering detectors nebulize the effluent, vaporize the solvent, and then detect 
droplets in a light scattering cell. 
Electrochemical detectors measure the current from the oxidation/reduction reaction of an 
analyte at a suitable electrode. 
Radiochemical detectors use tritium or carbon-14 to detect the fluorescence associated with 
beta-particle ionization. 
 Nuclear magnetic resonance detectors irradiate nuclei that are placed between the poles of 
a strong magnet. The radiation is absorbed, the parallel nuclei enter a higher energy state, and 
each atom produces a spectra specific to its location and chemical composition.  
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Fluorescence detectors that occurs when compounds are excited by shorter wavelength 
energy and emit higher wavelength radiation. 
ANALYTICAL METHOD DEVELOPMENT 
 Methods need to separate the desired components satisfactory, they need to generate the 
required results, and they must be reproducible and robust so that they can be used time after 
the time without problems. Methods are developed for new products when no official methos 
are available. Alternate methods  which  are not in pharmacopoeia for existing products are 
developed to reduce the cost and time for better precision and ruggedness. 
Method development steps: 
Step-1: Define method objectives and understand the chemistry 
 Determine the goals for method development (e.g., what is the intended use of the 
method), and to understand the chemistry of the analyte and the drugs product. 
Step-2 : Literature survey 
The literature for all types of information related to the analyte is surveyed. For synthesis, 
physical , chemical properties and relevant analytical methods.  Books, periodicals, chemical 
manufacturers and regulatory agency and other publications are reviewed.   
Step-3: Choosing a method 
Using the information in the literatures and prints, methodology is adopted. The methods 
are modified wherever necessary. If there are no prior methods for the analyte in the literature, 
the compounds that are similar in structure and chemical properties are investigated and 
worked out. 
Step-4: Initial HPLC conditions and optimization  
Develop preliminary HPLC conditions to achieve minimally acceptable separations. 
These HPLC conditions will be used for all subsequent method development experiment.  
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Step-5: Sample preparation procedure 
 Determine the appropriate standardization method and the use of relative response factors 
in calculations. 
Step-6: Standardization 
 Determine the appropriate standardization method and the use of relative response factors 
in calculations. 
Step-7: Final method optimization/robustness 
Identify the “weaknesses” of the method and optimize the method through experimental 
design. Understand the method performance with different conditions, different instrument set 
ups and different samples.  
Step-8:Evaluation of method development with actual samples 
The sample solution should lead to unequivocal, absolute identification of the analyte 
peak of interest apart from all other matrix components.  
Step 9: Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis 
Percent recovery of spiked, authentic standard analyte into a sample matrix that is shown 
to contain no analyte is determined.  Reproducibility of recovery (average +/- standard 
deviation) from sample to sample and whether recovery has been optimized has been shown.  
It is not necessary to obtain 100% recovery as long as the results are reproducible and known 
with a high degree of certainty.  
Step 9: method validation 
 Complete method validation according to ICH guidelines. 
Basic criteria for new method development of drug analysis:  
 The drug or drug combination may not be official in any pharmacopoeias, 
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 A proper analytical procedure for the drug may not be available in the literature 
due to patent regulations.  
 Analytical methods may not be available for the drug in the form of a 
formulation due to the interference caused by the formulation excipients. 
 Analytical methods for the quantitation of the drug in biological fluids may not 
be available. 
 Analytical methods for a drug in combination with other drugs may not be 
available. sThe existing analytical procedures may require expensive reagents 
and solvents. It may also involve cumbersome extraction and separation 
procedures and these may not be reliable.   
METHOD VALIDATION: 
 Method validation is the process used to confirm that the analytical procedure employed 
for a specific test is suitable for its intended use. Results from method validation can be used 
to judge the quality, reliability and consistency of analytical results; it is an integral part of 
any good analytical practice.  
 Analytical methods need to be validated or revalidated, 
 Before their introduction into routine use 
 Whenever the conditions change for which the method has been validated (e.g.,   
an instrument with different characteristics or samples with a different matrix). 
 Whenever the method is changed and the change is outside the original scope of 
the method. 
Method validation has received considerable attention in the literature and from industrial 
committees and regulatory agencies.  
 The U.S. FDA CGMP  request in section 211.165 (e) methods to be validated: 
The accuracy, sensitivity, specificity, and reproducibility of test methods 
employed by the firm shall be established and documented. Such validation and 
documentation may be accomplished in accordance with Sec. 211.194(a).  
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 ISO/IEC 17025 includes a chapter on the validation of methods  with a list of 
nine validation parameters.  
 The ICH has developed a consensus text on the validation of analytical 
procedures. The document includes definitions for eight validation 
characteristics. ICH also developed a guidance with detailed methodology 
 The U.S. EPA prepared a guidance for method‟s development and validation for 
the Resource Conservation and Recovery Act (RCRA) .  
Parameters of analytical method validation: 
 System suitability testing  
 Specificity 
 Linearity and range 
 Accuracy  
 Precision 
 Limit of detection 
 Limit of quantification 
 Robustness 
 Ruggedness  
SELECTIVITY AND SPECIFICITY: 
Selectivity is the ability to measure accurately and specifically the analyte in the presence  
of components that may be expected to be present in the sample matrix.                                           
Specificity for an assay ensures that the signal measured comes from the substance of                          
interest, and that there is no interference from excipient and/or degradation products                       
and/ or impurities. 
LINEARITY AND RANGE: 
Linearity- This is the method's ability to obtain results which are either directly, or after 
mathematical transformation proportional to the concentration of the analyte within a given 
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range. Linearity is determined by calculating the regression line using a mathematical 
treatment of the results (ie least mean squares) vs  analyte concentration. 
Range- The range of the method is the interval between the upper and lower levels of an 
analyte that have been determined with acceptable precision, accuracy and linearity.  
ACCURACY: 
Accuracy is a measure of the closeness of test results obtained by a method to the true 
value. Accuracy indicates the deviation between the mean value found and the true value. lt is 
determined by applying the method to samples to which known amounts of analyte have been 
added. These should be analysed against standard and blank solutions to ensure that no 
interference exists. The accuracy is then calculated from the test results as a  percentage of the 
analyte  recovered by the assay. Accuracy is best report as percentage bias, which is 
calculated from the expression.     
          (Measured value – True value) 
      %Bias =  -                                                x100                                                    
       True value 
PRECISION: 
The precision of an analytical method is the degree of agreement among individual test 
results obtained when the method is applied to multiple sampling of a homogenous sample.  
Precision is a measure of the reproducibility of the whole analytical method (including 
sampling, sample preparation and analysis) under normal operating circumstances. Precision 
is determined by using the method to assay a sample for a sufficient number of times to obtain 
statistically valid results (ie between 6 - 1 0). The precision is then expressed as the relative 
standard deviation. 
                                                     Standard deviation 
%RSD =    ______________      x 100 
Mean 
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LIMIT OF DETECTION: 
This is the lowest concentration in a sample that can be detected, but not necessarily 
quantitated, under the stated experimental conditions. The limit of detection is important for 
impurity tests and the assays of dosages containing low drug levels and placebos. The limit of 
detection is generally quoted as the concentration yielding a signal-to-noise ratio of 2:1 and is 
confirmed by analyzing a number of samples near this value (6) using the following equation. 
The signal-to-noise ratio (5) is determined by, 
       s = H/h 
Where H = height of the peak corresponding to the component h = absolute value of the 
largest noise fluctuation from the baseline of the chromatogram of a blank solution. 
The other method for calculating LOD is the standard deviation of the intercept (Sd), 
which may be related to LOD and the slope of the calibration curve, b  
         
                                                      3.3×Standard deviation 
                                LOD =                           Slope 
     
LIMIT OF QUANTIFICATION (LOQ): 
This is the lowest concentration of analyte in a sample that can be determined with 
acceptable precision and accuracy. 
lt is quoted as the concentration yielding a signal-to-noise ratio of 1 0: 1 and is confirmed 
by analyzing a number of samples near this value calculate by this formula 
                                10 ×Standard deviation 
                                LOQ =                           Slope 
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RUGGEDNESS: 
Ruggedness is the degree of reproducibility of results obtained by the analysis of the same 
sample under a variety of normal test conditions like different analysts, laboratories, 
instruments, reagents, assay temperatures, small variations in mobile phase, different days etc. 
( from laboratory to laboratory, from analyst to analyst). 
ROBUSTNESS: 
Robustness of an analytical method is measure of its capacity to remain unaffected small  
but deliberate variations in method parameters and provides an indication of its reliability 
during normal usage. 
Testing varying some or all condition: 
-Column temperature 
-PH of buffer in mobile phase 
-Reagents and flow rate 
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      I.1.OBJECTIVE 
   The objective of any analytical measurement is to obtain consistent, reliable data. 
Validated analytical methods play a major role in achieving this goal. The results from method 
validation can be used to judge the quality, reliability and consistency of analytical results, which 
is an integral part of any good analytical practice. 
  Analytical methods development and validation play important roles in the discovery, 
development, and manufacture of pharmaceuticals. 
 Pharmaceutical products formulated with more than one drug ,typically referred to as 
combination products ,are intended to meet previously unmet patients need by combining the 
therapeutic effects of two or more drugs in one product. Very  few methods are available for 
simultaneous estimation of multiple drug formulations. These combination products can present 
daunting challenges to the analytical chemist responsible for the development and validation of 
analytical method. Hence, it is essential to develop newer analytical methods which are accurate, 
linear, precise, specific, linear, simple and rapid. From the  literature survey it has been 
concluded that several methods were reported for estimation of  Indapamide and Nebivolol 
hydrochloride individually and only one or two methods are available for simultaneous 
estimation of these drugs. 
 Hence , the present work was thought to develop a precise, accurate, simple and reliable, 
less time consuming method for simultaneous estimation of indapamide and nebivolol 
hydrochloride by  RPHPLC.  
  DRUG PROFILE 
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                                               I.2. DRUG   PROFILE 
                                       INDAPAMIDE          
      STRUCTURE :               
                                           
                                          Chemical structure of Indapamide 
         
   CHEMICALNAME             :    4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl) 
       - 3-sulfomoyl benzamide 
 MOLECULAR FORMULA : C16H16ClN3O3S 
 MOLECULAR   WEIGHT  : 365.835g/mol 
 DESCRIPTION   : Yellow  to white coloured  powder 
 CATEGORY    : Thiazide- like(non-thiazide) diuretic drug 
 DOSE     : 1.25mg  to 5 mg 
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 Mechanism of action: 
 Indapamide   enhances excretion of sodium ,chloride and water by interfering with the 
transport of  sodium ions across the renal tubular epithelium.  It works by preventing  the 
kidney from reabsorbing salt and water that is destined to be eliminated in the urine. This 
results in increased urine output. 
 Indapamide also reduce salt in the smooth muscle of the walls of blood vessels. The loss 
of salt from the muscle causes the muscle to relax and the relaxation of the vessels results in 
reduced blood pressure. 
Indication:  
 For the treatment of hypertension, alone or in combination with  other    antihypertensive 
drugs, as well as for the treatment of salt and fluid retention associated with congestive heart 
failure lowering high blood pressure helps prevent strokes, heart attacks and kidney problems 
. 
Pharmacodynamics: 
       Indapamide is an antihypertensive and   a diuretic.   It contains both a polar  sulfamoyl  
chlorobenzamide moiety and a lipid-soluble methylindoline moiety. Chemically it does not 
possess the thiazid e ring system and     contains only one  sulfonamide group.  Indapamide 
appears to cause  vasodilation, probably by inhibiting the passage  calcium and   other ions 
 like sodium,potassium across membranes. 
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Pharmacokinetics :  
Absorption –rapidly and completely absorbed from GI tract. Peak plasma levels are 
achieved within   2-2.5 hours         
Distribution-Widely distributed,preferentially and reversibly bound to erythrocytes. 
Metabolism- Extensively metabolized in the liver. 
Excretion-Via urine (60-70% as metabolites,5-7% as unchanged),via faeces(16-23% 
remaining dose) 
Half life-14 hours 
Adverse effects: 
 Headache 
 Infection 
 Anxiety or tension 
 Chest pain 
 Depression 
 Indigestion 
  Runny nose 
 Sore throat 
 Coughing 
 Erectile dysfunction 
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   NEBIVOLOL   HYDROCHLORIDE 
Structure: 
 
 . Hcl 
                    Chemical structure of Nebivolol hydrochloride  
 
CHEMICAL NAME   : 1-(6-fluorochroman-2-yl)-2-[[-2-(6-fluorochroman-2-yl)-2-                                                 
    hydroxyethyl] amino] ethanol  hydrochloride 
MOLECULAR FORMULA :  C
22
H
25
F
2
NO
4
.HCl  
MOLECULAR WEIGHT  : 441.5g/mol 
DESCRIPTION   : white to off-white powders 
CATEGORY    : β-adrenergic receptor blocking agent 
DOSE    : 2.5 to 20mg 
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Mechanism of action: 
Nebivolol is a β1 receptor blocker with nitric oxide potentiating vasodilatory effect . In 
addition beta blockers prevent the release of renin, which is a hormone produced by the kidneys 
which leads to constriction of blood vessels. However, at doses above 10 mg nebivolol loses its 
selectivity and blocks both β1 and β2 receptors. 
Indication: 
Nebivolol hydrochloride used  in treatment  of hypertension and also treat cardiac failure. 
Pharmacodynamics: 
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   II.REVIEW OF LITERATURE 
1.)M.J.Legorburu et al
(12)
 (1999) carried out quantitative determination of indapamide in 
pharmaceuticals and urine by high-performance liquid chromatography with amperometric  
detection using a µBondapak C18 column with mobile phase consists of an acetonitrile: water 
mixture(45:55 , 5mM) in KH2PO4- KH2PO4(pH 4.0) and monitered with at + 1200 an 
amperometric  detector equipped with a glassy carbon working electrode. Percentage recovery 
are  88.3 ± 5.6 and 82.9 ± 7.8.  and linearity concentration range from 25 to 315 ng/mL. 
2.) LJ Patel et al
(3) 
(2007) developed  rphplc  and hptlc method  for estimation of nebivolol 
hydrochloride in tablet dosage form. For rphplc method  used lichrosper 100 C-18 column with 
mobile phase buffer(pH3.0±0.1):acetonitrile(45:55v/v) was used. Detection at 282nm and 
retention time was found to be3.76±0.02 min. For hptlc method linnomat V automatic sampler 
applicator, Hamilton syringe, camag TLC scanner-3,camag win CAT software with stationary 
phase precoated silica gel 60F 254 and mobile phase  toluene :methanol: ammonium hydrochloride 
(1:6:2:0.1v/v/v/v).The detection spot was carried out at 282nm and the R f value was found at 
0.33±0.02. the methods were validated in terms of linearity,accuracy and precsion. 
3.)Doshi,Ashish S et al
(8)
 (2008)developed and validated for the determination of nebivolol and 
valsartan in a capsule formulation by liquid chromatography with mobile phase buffer: 
acetonitrile  (55:45 v/v). The linearity was evaluated  over concentration range of 2-8 g/ml and 
32-128 g/microg/ml and the accuracy ranged from 100.66 to 102.58% and 101.17 to 101.85% for 
nebivolol and valsartan. 
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4.)DA Shah et al
(6)
 (2008) carried out stability indicating  RPHPLC method for determination of 
nebivolol hydrochloride in tablet dosage forms. A phenomax Gemini C-18 with mobile phase 
buffer(pH-4): methanol: acetonitrile (10:60:30 v/v/v). The retention time was 2.6 min. The 
linearity  was  in the range of 0.2-10 μg/ml. the recovery  was in the range 98.68-100.86%. 
5.)M.K.Sahoo et al
(9)
 (2009) carried out RP-HPLC method for the estimation of nebivolol in 
tablet dosage form. Chromatography was carried on a hypersil ODS C18  column using a mixture 
of methanol : water(80:20 v/v) as mobile phase at a flow rate of 1.0 ml/min with detection at 
282nm.The detector response was linear in the concentration of 1-400 μg/mL. The percentage 
assay of nebivolol was 99.974%. 
6.)M.S.Bhatia et al (2009) carried out simultaneous estimation of nebivolol hydrochloride and 
valsartan using RP-HPLC. The chromatographic method was standardized using a HIQ sil C-18 
column with UV detection at 289 nm and flow rate of 1ml/min.The mobile phase consisting of 
methanol:water(80:20 v/v) with addition of 0.1 percent 1-hexanesulfonic acid monohydrate 
sodium salt as an ion-pairing reagent was selected. 
7.) Y Gupta et al
(4)
 (2009) developed a new RP-HPLC method for simultaneous estimation of 
nebivolol hydrochloride and hydrochlorothiazide in pharmaceutical dosage forms using ultra 
violet detector. Mobile phase consisting of acetonitrile : buffer (pH 3.2 ± 0.1) in the ratio 
50:50v/v and flow rate was set on 1.2ml/min at 282 nm. The retention time  at 3.57 and 
6.66minutes and linear in the range of 20-80mg/ml and 8-32mg/ml for hydrochlorothiazide and 
nebivolol hydrochloride. 
8.)Mishra Vinay Kumar et al (2010) developed simultaneous estimation of amlodipine besylate 
and nebivolol hydrochloride in combined dosage form by RP-HPLC. The method was carried 
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out on a Luna C-18, 5µ with a mobile phase consisting of 0.005M ammonium acetate solution , 
acetonitrile and triethylamine in th ratio 60:40:0.1(v/v) with pH3.0 was adjusted with 
orthophosphoric acid. Detection was carried out at 269 nm at a flow rate of 1.5 ml/min. The 
retention time of amlodipine and nebivolol hydrochloride was 3.911 and 5.818 min and linearity 
was found in the range of 10-30µg/ml. 
9.) Amardeep Ankalgi et al (2011) developed RP-HPLC method for estimation of nebivolol in 
pharmaceutical dosage form. The method was carried out on a Hypersil BDS C-18 consisting of 
acetonitrile:0.3M potassium dihydrogen phosphate in ratio 50:50 (pH-3 adjusted with 
orthophosphoric acid) as mobile phase at a flow rate of 1.2ml/ min. Detection was carried out at 
278nm. The retention time of nebivolol was 4.34 min.   
10.) Paresh U.Patel  et al
(1)
 (2011) developed two spectroscopic  methods  for simultaneous 
estimation of indapamide and nebivolol hydrochloride in combined tablet dosage. The first was 
simultaneous equations method formation of simultaneous equations at 241.6nm and 281.5nm, 
linearity   concentration range was 2-12?g/ml and 10-50?g/ml for indapamide and nebivolol  
hydrochloride. The second was Q- analysis method formation of Q-absorbance equation at 
274nm and 281.5nm, linearity concentration range was 2-20g/ml for both indapamide and 
nebivolol hydrochloride. 
11.)Pawar Prachi Vasant et al
(7) 
(2011) developed and validated for the estimation of atenolol 
and indapamide  in bulk and tablet dosage forms by rphplc.C-18 column with mobile phase 
methanol: water: diethylamine: glacial acetic acid(70:30:0.12:0.08)  in isocratic mode at a flow 
rate of 1.2ml/min. th e detection at 240nm.The  linearity range  from  20-100 μg/ml and 1-5 
μg/ml for atenolol   and  indapamide. 
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12.) A.Sathish Kumar Shetty, Jyoti B.Pai, et al
(2) 
(2011) developed  RPHPLC method for 
quantitative estimation  of indapamide in bulk and pharmaceutical dosage forms. 
Chromatography was performed on a supelco RPC-18 column with mobile phase buffer(pH 3): 
acetonitrile (60:40) at flow rate 1ml/min, detection at 240 nm. Retention time at  6.76 ± 0.0145 
min, linear calibration plots were obtained between 10-100μg/ml. 
13.)Hitendra S.Joshi et al
(5)
 (2011) hplc method development and validated  for assay of 
combine dosage form of atenolol and indapamide in commercial tablets. RPHPLC analysis was 
performed on a phenomenex make Gemini C18 column with mobile phase buffer (pH-3) : 
acetonitrile (50:50v/v)  detection at 241nm. Linearity range 0.2-0.8mg/ml and accuracy was 
between 98.02 and 100.51%. 
14.)S.J. Dighade et al (2011) developed RP-HPLC method for simultaneous estimation of 
nebivolol  hydrochoride and amlodipine  besilate in tablet dosage forms. The separation was 
achieved by C18 intersil column with mobile phase containing methanol : acetonitrile : 
50mMkH2PO4  buffer (25:30:45 v/v, pH 3.0). UV detection was carried out at 267 nm.  The 
retention time for nebivolol hydrochloride and amlodipine besilate was 7.63 min and 3.34 min 
and linearity was 10-100 µg/ml for both the drugs. 
15.)Patel Amit R et al
(10)
 (2011) developed stability- indicating assay method for simultaneous 
determination of  telmisartan and indapamide in a formulation in the presence of its degradation 
products and  separation from their associated main impurities and degradation products. 
Amazon C18 column used with mobile phase buffer(pH-3): acetonitrile: methanol(45:25:30)  
flow rate 1ml/mim and uv detection at 285nm. Retention time at 4.7 min and 10.7 min, linearity 
in the range of  6-22.5 micro g/ml and 11.2-42 micro g/ml for telmisartan and indapamide.  
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          III. EXPERIMENTAL WORK 
    METHOD DEVELOPMENT 
Instruments used: 
Analytical balance  -  unibloc model ; shimandzu,libror 
HPLC    -  LC-2010 ; shimandzu corporation Japan  
UV    -  UV-2550 ; shimandzu corporation Japan  
Chemicals used: 
 Water- HPLC grade 
 Methanol- HPLC grade 
 Acetonitrile- HPLC graded 
 Potassium dihydrogen phosphate-  AR grade 
 Dipotassium hydrogen phosphate- AR grade 
 0.1M sodium hydroxide- AR grade 
 Hydrochloric acid- AR grade 
 Ortho phosphoric acid- AR grade 
Drug sample: 
Indapamide, Nebivolol hydrochloride sample obtained from Chandra labs Pvt.Ltd.,          
Hyderabad. 
Initialization of the instrument: 
Initialy, the column was placed on the instrument and switch on the instruments and washed 
in methanol: water (20:80) for 30 min. Then the system was made to run with the mobile 
phase for 30 min. 
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TRAILS: 
1. Trail-I 
1.1. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile:water in the ratio of 65:35 and filtered through 
0.45 micron membrane filter. 
2. Trail-II 
2.1. Preparation of mobile phase: 
Filtered and degassed mixture of water:methanol in the ratio of 30:70 and filtered through 
0.45 micron membrane filter. 
3. Trail-III 
3.1. Preparation of Buffer: 
Taken 1.1818 gms of  potassium  dihydrogen  phosphate  and  was dissolved in 500ml of 
water and adjust the pH-3 using  Ortho-phosphoric acid. 
3.2. Preparation of mobile phase: 
Filtered and degassed mixture of buffer : acetonitrile in the ratio of 35:65 and filtered through 
0.45 micron membrane filter. 
 
4. TRAIL-IV  
4.1. Preparation of Buffer: 
Taken 1.1818gms of   potassium  dihydrogen  phosphate and 0.218gms of Dipotassium 
hydrogen  phosphate was dissolved in 500ml of water and adjusted the pH-3using  Ortho-
phosphoric acid. 
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4.2. Preparation of mobile phase:  
Filtered and degassed mixture  of  buffer : acetonitrile in the ratio of 40:60 and filtered 
through 0.45 micron membrane filter. 
5. ASSAY 
5.1. Preparation of standard solution: 
Taken  15 mg of indapamide and 25 mg of nebivolol in 50 ml volumetric flask. Dissolved in 
methanol and diluted to volume with mobile phase. Transferred 0.5 ml from stock solution to 
10 ml volumetric flask and made up to the volume with mobile phase. 
5.2. Preparation of sample solution: 
Weighed 10 tablets, calculated the average weight , powdered, weighed 500mg and 
transferred to 50 ml volumetric flask. Dissolved in methanol and diluted to volume with 
mobile phase, transferred 0.5 ml  to 10 ml volumetric flask and made up to the volume with 
mobile phase. 
Calculation: 
   AT  WS  DT  P   Avg.Wt   
Assay%=                            X                     X                    X                  X                  X      100 
   AS  DS  WT            100   Label claim 
Where, AT = average area counts of sample preparation. 
      AS= average area counts of standard preparation. 
      WS = Weight of working standard taken in mg. 
      P     = Percentage purity of working standard 
      LC =     label claim 
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6. VALIDATION: 
6.1 System suitability 
6.1.1. Preparation of stock solution: 
Taken  15 mg of indapamide and 25 mg of nebivolol hydrochloride in 50 ml volumetric 
flask. Dissolved in methanol and  diluted to volume with mobile phase. 
6.1.2. Dilution  
Transferred 0.5  ml from stock solution  to 10 ml volumetric flask and made up to the volume 
with mobile phase. 
6.2. SPECIFICITY 
Check for interference from blank, diluents was used as blank. 
6.2.1. Preparation of standard solution: 
Taken 15 mg of indapamide and  25 mg of nebivolol in 50 ml volumetric flask. Dissolved in 
methanol and diluted to volume with mobile phase. Transferred 0.5 ml from stock solution to 
10 ml volumetric flask and made up to the volume with mobile phase. 
6.2.2 Preparation of sample solution: 
Weighed 500mg of powdered sample and transferred to 50 ml volumetric flask. Dissolved in 
methanol and diluted to volume with mobile phase, transferred 0.5 ml  to 10 ml volumetric 
flask and made up to the volume with mobile phase. 
6.2.3. Preparation of stock solution: 
Taken 15 mg of  indapamide and 25 mg of nebivolol hydrochloride in 50 ml volumetric 
flask. Dissolved in methanol  and  diluted to volume with mobile phase. 
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6.2.4.Tested under stress conditions: 
i.)Heated on water bath: 
Taken 0.5 ml from the stock solution and transferred to 10 ml volumetric flask, made upto to 
the volume with mobile phase. The solution should be heated 40
o
C for 30 minutes. Observed 
for any degradation occurred. 
ii.) Treated with Acids: 
Taken 0.5 ml from the stock solution and transferred to a 10 ml volumetric flask. Added1ml 
of 0.1M hydrochloric acid to that solution and made up to the volume with mobile phase. 
Observed for any change took place in the retention of the peak. 
iii.) Treated with base: 
Taken 0.5 ml from the stock solution and transferred to a 10 ml volumetric flask.  Added1 ml 
of 0.1M sodium hydroxide to that solution and made up to to the volume with mobile phase 
Observed for any degradents occurred. 
 6.3.LINEARITY 
6.3.1. Preparation of stock solution: 
Taken 15mg of indapamide and 25 mg of nebivolol in  50 ml volumetric flask. Dissolved in 
methanol  and  diluted to volume with mobile phase. 
6.3.2. Preparation of linearity solution-I: Transferred 0.1ml from stock solution to 10 ml 
Volumetric flask and made up with mobile phase( the solution become 3 mcg of indapamide 
and 5 mcg of nebivolol hydrochloride). 
6.3.3. Preparation of linearity solution-II: Transferred 0.2ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 6 mcg of indapamide 
and 10 mcg of nebivolol hydrochloride). 
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6.3.4. Preparation of linearity solution-III: Transferred 0.3ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 9 mcg of indapamide 
and 15 mcg of nebivolol hydrochloride). 
6.3.5. Preparation of linearity solution-IV: Transferred 0.4ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 12 mcg of indapamide 
and 20mcg of nebivolol hydrochloride). 
6.3.6. Preparation of linearity solution-V: Transferred 0.5ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 15 mcg of indapamide 
and 25mcg of nebivolol hydrochloride). 
6.3.7. Preparation of linearity solution-VI: Transferred 0.6ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase (the solution become 18 mcg of indapamide 
and 30 mcg of nebivolol hydrochloride). 
6.4. ACCURACY: 
6.4.1. Preparation of stock solution: 
Taken 15 mg of indapamide and 25 mg  of nebivolol hydrochloride in 50 ml volumetric 
flask. Dissolved in methanol and  diluted to volume with mobile phase.  
6.4.2. Preparation of spiking standard:  
Transferred 0.5 ml from stock solution to 10ml volumetric flask made up with mobile phase. 
6.4.3. Preparation of Accuracy solution 1: Transferred  0.4ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 12 mcg of indapamide 
and 20 mcg of nebivolol hydrochloride) and added 1ml of spiking standard. 
6.4.4. Preparation of Accuracy solution  2: Transferred  0.5ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 15 mcg of indapamide 
and 25 mcg of nebivolol hydrochloride) and added 1ml of spiking standard. 
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6.4.5. Preparation of Accuracy solution  3: Transferred  0.6ml from stock solution to 10 ml 
volumetric flask and made up with mobile phase( the solution become 18 mcg of indapamide 
and 30 mcg of nebivolol hydrochloride) and added 1ml of spiking standard. 
6.5 PRECISION 
6.5.1. System precision: 
Preparation of standard solution: 
Taken 15 mg of indapamide and  25 mg of nebivolol hydrochloride in 50 ml volumetric 
flask. Dissolved in methanol and diluted to volume with mobile phase. Transferred 0.5 ml 
from Stock solution to 10 ml volumetric flask and made up to the volume with mobile phase. 
6.5.2. Method precision: 
Preparation of sample solution: 
Weighed 500mg of sample and transferred to 50 ml volumetric flask. Dissolved in  methanol 
and diluted to volume with mobile phase, transferred 0.5ml  to 10 ml volumetric flask and 
made up to the volume with mobile phase. 
6.5.3. Intermediate precision (ruggedness): 
The intermediate precision was performed by two analyst on different instrument and 
different day with the solution used for the method precision.  
6.6. ROBUSTNESS:  
6.6.1. Preparation of stock solution: 
Taken 15 mg of indapamide and 25 mg of nebivolol  hydrochloride in 50 ml volumetric 
flask. Dissolved in methanol  and  diluted to volume with mobile phase. 
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6.6.2. Dilution: 
Transferred 0.5 ml from stock solution to 10ml volumetric flask made up with mobile phase 
(the solution become 15 mcg of indapamide and 25 mcg of nebivolol hydrochloride). 
6.7. LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTIFICATION (LOQ): 
The LOD and LOQ of the drug were derived by visually or calculating the signal- noise ratio. 
In this method the LOD and LOQ of the drug were calculated by following equation.    
                           3.3×Standard deviation 
                                        LOD =                                         
           Slope 
 
                        10.×Standard deviation 
                                         LOQ =                       
Slope 
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   IV.RESULTS AND DISCUSSION 
 
1. TRAILS 
1.1. Trail-I: 
System suitability results for  Indapamide and Nebivolol hydrochloride 
1.) Tailing factor obtained from trail- I was 1.600 and 1.515 
2.) Theoretical plates obtained from trail-I was 1353 and 2378 
3.) Resolution obtained from trail-I was 12.593   
4. )Retention time obtained from trail-I was 1.8 and 6.4  
1.2. Trail-II 
System suitability results for Indapamide and Nebivolol hydrochloride 
1.) Tailing factor obtained from trail-II was 1.333 and 2.192 
2.) Theoretical plates obtained from trail-II was 2372 and 2898 
3.) Resolution obtained from trail-II was 18.534 
4.) Retention time obtained from trail-II was 1.7 and 10.1 
1.3. Trail-III: 
System suitability results for Indapamide and Nebivolol hydrochloride 
1.) Tailing factor obtained from trail-III was 1.074 and 1.159 
2.) Theoretical plates obtained from trail-III was 1551 and 7793 
3.) Resolution obtained from trail-III was  17.843 
4.) Retention time obtained from trail-III was 1.6 and 9.6. 
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1.4.Trail-IV: 
System suitability results for Indapamide and Nebivolol hydrochloride 
1.) Tailing factor obtained from trail-IV was 1.429 and 1.250 
2.) Theoretical plates obtained from trail-IV was 6081 and 7394 
3.) Resolution obtained from trail-IV was 7.416 
4.) Retention time obtained from trail-IV  was 2.54 and 3.65 
Trails results: 
on  the  evaluation  of above system suitability  results, 
 In trail-I and trail-II the   tailing factor should to be reduced. 
 In trail-I  and  trail-III the theoretical plates should to be increased , resolution should  to 
be reduced. 
 System suitability parameters of  trail-IV were within the  satisfactory limits.  
 Hence trail I,II, III shows variation  in system suitability results  and  affected the method  
significantly .Trail-IV  shows  good system suitability results and  also within in the limit so the 
trail – IV was adopted. 
 
Table no-2: OPTIMIZED METHOD PARAMETERS: 
                PARAMETERS                       CONDITIONS 
Column(Stationary Phase) BDS HYPERSIL C18  (4.6 x 150mm, 5 m 
Mobile Phase Phosphate Buffer(3.0pH):Acetonitrile(40:60) 
Flow rate (ml/min)                                     1 
Run time (min)                                    20 
Column temperature(°C)                             Ambient 
Volume of injection loop ( l)                                    20 
Detection wavelength (nm)                                   235 
Drug RT (min)                            2.54,3.65 
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  2. ASSAY 
In HPLC ,injected  the standard and sample solution  prepared as per procedure 5.1 and 5.2 and 
the results were calculated as per the formula given in assay procedure(5).    
                       Table no-3: Assay results of indapamide 
 
 
 
 
 
 
 
 
                           Table no-4 : Assay results of nebivolol hydrochloride 
 
                            
 
 
 
 
 
   
INDAPAMIDE 
  Standard Area 1 330.677 
 
2 333.248 
 
3 332.291 
 
Average 332.072 
   Sample area 1 332.830 
 
2 329.576 
 
Average 331.203 
Tablet average weight 
 
50.4 mg 
Standard weight 
 
15mg 
Sample weight 
 
500.9 mg 
Label amount 
 
1.5 mg 
std.purity 
 
99.86% 
Cal.: 
 
1.503 mg 
 
%Assay 100.21 % 
Nebivolol HCL  
  Standard Area 1 808.412 
 
2 805.524 
 
3 805.524 
 
Average 806.486 
   Sample area 1 805.228 
 
2 807.116 
 
Average 806.172 
Tablet average weight 
 
50.4 mg 
Standard weight 
 
25mg 
Sample weight 
 
500.9 mg 
Label amount 
 
2.5 mg 
Std.purity 
 
99.85% 
Cal.: 
 
2.510 mg 
 
%Assay 100.42 % 
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  Result : 
 From the assay studies, it was found that the formulation contains 100.21% of             
indapamide and 100.42%.of  nebivolol hydrochloride. 
VALIDATION RESULTS 
1. System suitability: 
In HPLC, injected the solution prepared as per the procedure 6.1 and recorded the peak response of 
the chromatogram. 
                 Table no-5 : System suitability results for indapamide 
S.No Parameter Indapamide 
1 RT(min) 2.51 
2 Tailing Factor 1.429 
3 No. of  theoretical plates 6081    
 
                   Table no- 6 :  System suitability results for nebivolol hydrochloride 
S.No Parameter Nebivolol hydrochloride 
1 RT(min) 3.62 
2 Tailing Factor 1.250 
3 No.of  theoretical plates                     7394 
 
Result : 
On the evaluation of above results it was found that all the system suitability parameters were 
within the satisfactory limit. 
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2. SPECIFICITY: 
Diluents ,standard preparation and assay  were prepared as per the method (6.2) and the solutions 
were injected into the HPLC and the chromatograms recorded. The retention time were given in 
the following table, 
               Table no-7: Specificity results for indapamide and nebivolol hydrochloride 
S.No Solutios Retention time(min) 
1. Indapamide Standard preparation                   2.52 
2. Indapamide assay preparation                  2.51 
3. Nebivolol Hcl standard preparation                  3.63 
4. Nebivolol Hcl assay preparation                  3.62 
 
 
           Table no-8: Specificity results for indapamide and nebivolol hydrochloride under 
           stress conditions 
                                  
 
 
 
Result : 
i.) No peaks should be detected at the retention time of indapamide and nebivolol hydrochloride 
in the chromatograms of diluents preparation  
ii.) From the stress conditions performed, various degradation products were formed and there 
was no change in the detection of the analyte in the presence of other components. 
 
S.No Stress conditions Observed Result  
1. Heated on water bath No degradation occurred 
2. Treated with acids No change in retention of the peak 
3. Treated with base No degradents formed 
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3. LINEARITY 
In HPLC,injected the each concentration of the solution prepared as per the method (6.3) and the 
results were given in the following tables, 
Table no-9: Linearity Results: (for indapamide) 
S.No Linearity Level Concentration (mcg) Area (mV.s) 
1 I 3 68.577 
2 II 6 136.152 
3 III 9 189.157 
4 IV 12 228.469 
5 V 15 284.891 
6 VI 18 332.874 
                                        Correlation Coefficient                                                   0.997 
  
Figure No-1: calibration plot for indapamide: 
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Table no-10: Linearity Results: (for nebivolol hydrochloride) 
S.No Linearity Level Concentration (mcg) Area (mV.s) 
1 I 5 
157.532 
2 II 10 
301.879 
3 III 15 
436.291 
4 IV 20 
552.655 
5 V 25 
666.779 
6 VI 30 
790.165 
      Correlation Coefficient       0.998     
  
 
 Figure No:2 calibration plot for nebivolol hydrochloride:  
                                      
Acceptance criteria: 
Correlation coefficient should be not less than 0.9 
Results : 
On evaluation of above results % RSD values are within the limit hence the curve shows 
linearity at concentration range 3µg/ml-18µg/ml for indapamide and 5µg/ml-30µg/ml for 
nebivolol hydrochloride. 
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4. ACCURACY:  
In HPLC, injected each concentration of the solution prepared as per the method(6.4) and the 
results were given in the following tables, 
  Table no: 11 Accuracy results for indapamide 
 %Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mcg) 
Amount 
Found 
(mcg) 
% 
Recovery 
Mean 
Recovery 
80% 262.1347 13.5 13.46 99.70% 
99.22% 100% 318.4707 16.5 16.31 98.84% 
120% 368.3263 19.5 19.33 99.12% 
                      Table no-12: Accuracy results of nebivolol hydrochloride: 
%Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mcg) 
Amount 
Found 
(mcg) 
% Recovery 
Mean 
Recovery 
80% 637.1297 22.5 22.31 99.16% 
99.21% 100% 777.3993 27.5 27.22 98.98% 
120% 883.5633 32.5 32.34 99.50% 
 Acceptance Criteria: 
 The % Recovery for each level should be between 98.0 to 102.0%. 
Results : 
From the results shown in accuracy, it was found that the percentage recovery values of  pure 
drug from the pre analyzed solutions of formulations were in between  99.22% for indapamide, 
99.21% for nebivolol hydrochloride, which indicates that the method was  accurate. 
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5. PRECISION: 
In HPLC,injected six replicate injection of the solution prepared as per the method(6.5) and the 
results were given in the following table, 
5.1 System precision: 
               Table no- 13: System precision results of indapamide   
 
 Injections Area[mv.s] 
1 285.986 
2 287.305 
3 285.395 
4 289.254 
5 286.513 
6. 284.562 
Avg 286.5025 
Std dev 1.641569 
%RSD 0.60 
  Table no-14 System precision results for nebivolol hydrochloride 
Injections Area[mV.s] 
1 685.131 
2 680.701 
3 676.947 
4 679.709 
5 680.747 
6 679.988 
Avg 680.5372 
Std dev 2.647675 
%RSD 0.40 
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5.2. Method precision: 
  Table no -15: Method precision results for indapamide 
Injections Area[mV.s] 
1 280.641 
2 281.961 
3 281.057 
4 282.752 
5 281.340 
6 283.343 
Avg 281.9502 
Std dev 1.157837 
%RSD 0.4 
 
  Table no-16: Method precision results for nebivolol hydrochloride 
 
 
 
Acceptance Criteria: 
  The % RSD for the area of five standard injections results should not be more than 2%. 
Injections Area[mV.s] 
1 682.656 
2 684.543 
3 684.116 
4 683.652 
5 690.639 
6 683.454 
Avg 684.8433 
Std dev 2.910083 
%RSD 0.5 
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Result : 
From the results shown in precision, it was found that % RSD is less than 2%; which indicates 
that the proposed method has good reproducibility. 
 5.3. Intermediate precision( ruggedness):  
Table no-17: Intermediate precision results for indapamide 
Injections Area [mV.s] 
 Analyst-1 Analyst-2 
1 283.566 283.524 
2 280.452 284.433 
3 282.421 282.455 
4 283.433 282.754 
5 281.543 284.653 
6 282.233 282.335 
Avg 282.2747 283.5257 
Std dev 1.173872 0.906894 
%RSD 0.41 0.31 
     Table no-18: Intermediate precision results for nebivolol hydrochoride 
Injections Area [mV.s] 
 Analyst-1 Analyst-2 
1 680.323 681.09 
2 683.376 683.544 
3 683.455 683.423 
4 685.431 685.573 
5 683.747 685.431 
6 684.412 685.443 
Avg 683.4573 684.084 
Std dev 1.715886 1.764708 
%RSD 0.30 0.31 
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6. ROBUSTNESS: 
The robustness of the method established by making  minor variations in the  method parameters 
like, change  in flow rate by ± 10 % of actual flow rate . 
 
 Table no-19: Robustness results for indapamide 
   
S.No 
 
Flow Rate (ml/min) 
System Suitability Results 
USP Plate Count USP Tailing 
1             0.9 2242 1.5 
2 1.0 6081               1.4 
3      1.1        3283              1.6 
       
 
 Table no-20: Robustness results for nebivolol hydrochloride 
   
S.No 
 
Flow Rate (ml/min) 
System Suitability Results 
USP Plate Count USP Tailing 
1             0.9 2804 1.6 
2 1.0                 7394              1.2 
3      1.1         3176              1.6 
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Result:  
The flow rate was varied at 1.0 ml/min to 1.2ml/minThe results are summarized On evaluation of 
the above results, it can be concluded that the variation in flow rate affected he method 
significantly. Hence it indicates that the method is not robust even by change in the flow rate 
±10%. 
7. LIMIT OF DETECTION: 
Table no-21:Limit of detection results 
Drug Name Standard Deviation Slope Result 
(µg/ml) 
Indapamide                1.641569      17.21 0.30 
Nebivolol hydrochloride               2.647675      24.996    0.95 
 
 
8. LIMIT OF QUANTIFICATION: 
Table no-22: Limit of quantification results 
Drug Name Standard Deviation Slope Result 
(µg/ml) 
Indapamide 1.641569 17.21 0.31 
Nebivolol hydrochloride 2.647675 24.996 1.05 
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V.SUMMARY AND CONCLUSION 
 
An attempt has been made to develop the RP-HPLC method for simultaneous 
estimation of indapamide and nebivolol hydrochloride in combined dosage form. As the 
literature survey revealed that few methods were available for  their simultaneous estimation, 
but there is a need of a simple, economical and proper method for estimation of above 
combination in combined dosage form. 
Water’s- HPLC with Empower2 software, UV detector and  with BDS HYPERSIL C18
 
Column (4.6mm X 150 mm, 5µm), an injection volume of 20μl is injected and eluted with the 
mobile phase of  phosphate buffer (pH3.0):Acetonitrile (40:60), which was pumped at a flow 
rate of 1ml/min and detected by UV detector at 235 nm. The peaks of indapamide and 
nebivolol hydrochloride were found well separated at , 2.54 and 3.65 respectively. 
From the assay studies, it was found that the formulation contains 100.12% of 
indapamide and 100.32%.of  nebivolol hydrochloride. 
 The system suitability studies showed that all the system suitability parameters were 
within the acceptance criteria and  the drug obeys linearity within the concentration range of 3- 
18 g/ml for indapamide, 5-30 g/ml for nebivolol hydrochloride.. 
 Accuracy results showed that the percentage recovery values of pure drug from the pre 
analyzed solutions of formulations were in between 99.22% for indapamide, 99.21% for 
nebivolol hydrochloride, which indicates that the method was accurate and the precision results 
concludes that % RSD is less than 2%; which indicates that the proposed method has good 
reproducibility.  
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From the results shown in Robustness, it was found that there is little change in the 
results with the change in the parameters like flow rate  indicating the robustness of the method 
and in the ruggedness,  the %RSD is less than 2% for the results of two analyst indicating the 
ruggedness of the method.  
 The developed chromatographic method for the determination of indapamide and 
nebivolol hydrochloride  in tablet dosage forms was simple, rapid, accurate, precise, specific, 
robust and economical. Therefore this method may be adopted for the routine analysis of 
Indapamide and Nebivolol hydrochloride in pharmaceutiacal tablet formulation. 
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